Northwest Biotherapeutics reported $80.05M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Celldex Therapeutics USD 782.35M 271.09M Jun/2026
Eisai JPY 1.56T 108.98B Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Northwest Biotherapeutics USD 80.05M 49.44M Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Plus Therapeutics USD 14.03M 5.89M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026